BioCentury
ARTICLE | Clinical News

BlackThorn begins Phase IIa of BTRX-246040 for MDD

July 28, 2017 6:32 AM UTC

BlackThorn Therapeutics Inc. (South San Francisco, Calif.) began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate BTRX-246040 for 8 weeks in about 100 patients with major depressive disorder (MDD) with or without anhedonia. Patients will receive once-daily 40 mg oral BTRX-246040 for the first week followed by once-daily 80 mg oral BTRX-246040 for weeks 2-8...